BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
Mechanistic comparison of lithospermum erythrorhizon and mylabris phalerata based on molecular target overlap from BindingDB and ChEMBL binding affinity data.
lithospermum and mylabris share 2119 molecular targets based on binding affinity data from BindingDB (Kd/IC50 ≤ 10 µM) and ChEMBL. A Jaccard index of 0.532 means 53% of the combined target set is bound by both compounds. The IDF-weighted score of 0.506 accounts for non-specific binding to metabolic enzymes.
Note: High target overlap does not imply identical mechanism or therapeutic equivalence. Binding affinity, tissue distribution, bioavailability, and downstream signaling differ significantly between compounds even when they bind the same protein.
Frequently Asked Questions
What do lithospermum and mylabris have in common?
lithospermum and mylabris share 2119 molecular targets with a Jaccard similarity of 53%. Both bind overlapping sets of proteins based on BindingDB and ChEMBL binding affinity data.
Can lithospermum and mylabris be combined?
lithospermum and mylabris share 2119 molecular targets, suggesting potential pathway overlap. Combination use should be evaluated with a qualified healthcare professional. BiohacksAI does not provide medical advice.
Which has more research: lithospermum or mylabris?
In the BiohacksAI corpus: lithospermum has 200 PubMed-indexed studies, mylabris has 37 studies.